Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Jason Zhu"'
Publikováno v:
Frontiers in Blockchain, Vol 7 (2024)
Blockchains are significantly easing trade finance, with billions of dollars worth of assets being transacted daily. However, analyzing these networks remains challenging due to the sheer volume and complexity of the data. We introduce a method named
Externí odkaz:
https://doaj.org/article/04f6c618302a44acbdd2c8d3e8f4532d
Autor:
Tian Zhang, Carl Morrison, Sarabjot Pabla, Jason Zhu, Matthew Zibelman, Shannon McCall, Sean T Glenn, Saby George, Yong Hee Lee, Landon C Brown, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Laura J Tafe, Farshid Dayyani, Kunal Desai, Moshe C Ornstein, Emily Kinsey, Jennifer Tran, Konstantin H Dragnev, Mary K Nesline
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorabl
Externí odkaz:
https://doaj.org/article/9b968140c98748eb94a5b6265a763e29
Autor:
Matthew D. Tucker, Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Harrison, Yuan Wu, Patrick Healy, Stacey Lisi, Daniel J. George, Andrew J. Armstrong
Publikováno v:
Cancer Medicine, Vol 8, Iss 10, Pp 4644-4655 (2019)
Abstract Background Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)‐high or mismatch repair‐deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies.
Externí odkaz:
https://doaj.org/article/003ea2a11f594b2c9c3a564cda4a8f56
Autor:
Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Wang Yirong, Grace K. Dy, Edwin Yau, Amy Early, Hongbin Chen, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Daniele Marin, Jason Zhu, Jeff Clarke, Matthew Labriola, Shannon McCall, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Arun Singavi, Ben George, Andrew Craig MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Lynn Dressler, Mark Steciuk, Oliver Binns, Deepa Kasuganti, Neel Shah, Marc Ernstoff, Kunle Odunsi, Razelle Kurzrock, Mark Gardner, Lorenzo Galluzzi, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other
Externí odkaz:
https://doaj.org/article/4f4efc20d258452fa94c335442c051f9
Autor:
Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each develope
Externí odkaz:
https://doaj.org/article/ba0a2468e04d487e8d2b8fe0e2e078e6
Autor:
Ramy Sedhom, Santosh Gupta, Yuan Wu, Jason Zhu, Daniele Marin, Michael R Harrison, Landon C Brown, Matthew D Tucker, Eric B Schwartz, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Emmanuel S Antonarakis, Andrew J Armstrong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI).Methods We co
Externí odkaz:
https://doaj.org/article/f6c317e45ad243c18c3fdb3ae41b8601
Autor:
Rajan Gupta, Tian Zhang, Jason Zhu, Shannon McCall, James R White, Matthew Kyle Labriola, Jennifer Jackson, Eric F Kong, Gustavo Cerqueira, Kelly Gerding, John K Simmons, Daniel George
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Immune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers for response to ICIs in this indication, with programmed death-ligand 1 (PD-L1
Externí odkaz:
https://doaj.org/article/ca123fda1f6346a9abc716913c23a26c
Autor:
Tian Zhang, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Vincent Giamo, Jonathan Andreas, Yirong Wang, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Rajan Gupta, Jason Zhu, Matthew Labriola, Shannon McCall, Daniel J. George, Pooja Ghatalia, Farshid Dayyani, Robert Edwards, Michelle S Park, Rajbir Singh, Robin Jacob, Saby George, Bo Xu, Matthew Zibelman, Razelle Kurzrock, Carl Morrison
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Background Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utili
Externí odkaz:
https://doaj.org/article/a9d163d7634140f1b36ef03f7b72ba6d
Autor:
Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, Tian Zhang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Abstract Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict fo
Externí odkaz:
https://doaj.org/article/60c2e401c65c4ce9b770b3cffe78bbfe
Autor:
Jinsheng (Jason) Zhu, Yan Ma, Guoen Xia, Salle, Sabariah Mohamed, Hongye Huang, Sannusi, Shahrul Nazmi
Publikováno v:
Frontiers in Psychology; 2024, p1-13, 13p